Astellas Gene Therapies (Astellas Gene) is a biotechnology company that focuses on the development and commercialization of gene therapy products for rare diseases. The company’s major pipeline products include AT132, AT845, ASP2016, AT466 and KT430. It's products are used for the treatment of X-linked myotubular myopathy, pompe disease, muscular dystrophy in children and neuromuscular disease, severe respiratory insufficiency, weakness and hypotonia. The company is currently exploring three gene therapy modalities such as gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. Astellas Gene is headquartered in San Francisco, California, the US.
Astellas Gene Therapies premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
AT132 - X-linked Myotubular Myopathy |
AT845 - Pompe Disease |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Astellas Gene Therapies | Amicus Therapeutics Inc | Nektar Therapeutics | Capsida Biotherapeutics Inc | Dimension Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | San Francisco | Philadelphia | San Francisco | Thousand Oaks | Cambridge |
State/Province | California | Pennsylvania | California | California | Massachusetts |
No. of Employees | - | 517 | 137 | - | - |
Entity Type | Private | Public | Public | Private | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Morten Sogaard | Head - Division; President | Senior Management | - | - |
Don Mather | Senior Vice President - BioPharma Manufacturing | Senior Management | - | - |
Richard Wilson | Senior Vice President - Primary Focus Lead – Genetic Regulation | Senior Management | - | - |
David Smethurst | Head - Regulatory Affairs; Vice President | Senior Management | - | - |
Amy Pott | Senior Vice President - Commerical | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer